Clinical Trials on Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII

Total 1 results

University of Pennsylvania

Completed

Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies

Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII Infusion

United States

3

Subscribe